Andreessen Horowitz unveils $450 mln second bio fund

KKR, Kohlberg Kravis Roberts, healthcare, private equity, Slayback Pharma, pharmaceuticals
Stethoscope and $100 bills symbolizing healthcare spending and the affordable care act. Photo courtesy Photopa1/iStock/Getty Images
Andreessen Horowitz unveiled a $450 million second biotech fund targeting the intersection of biology and engineering, according to a blog post. The firm launched its first bio fund in 2015 with $200 million of capital. As with the first fund, ...

Take your pick!

  • Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
  • VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.

PE Hub Healthcare Wire delivers private equity and M&A healthcare deal activity, fundraising news, people moves, regulatory updates and much more every Thursday. Subscribe now! It’s FREE.

This content is available for Venture Capital subscribers only. Request a free trial to get access for a limited period

Venture Capital

Subscribe Now Request Trial

If you already have an active Venture Capital subscription, please sign in to view this article.